Cardiovascular risk assessment in metabolic syndrome: view from PROCAM

被引:18
|
作者
Assmann, G
Nofer, JR
Schulte, H
机构
[1] Univ Munster, Inst Klin Chem, D-48129 Munster, Germany
[2] Univ Munster, Lab Med, D-48129 Munster, Germany
[3] Univ Munster, Inst Arterioskleroseforsch, D-4400 Munster, Germany
关键词
D O I
10.1016/j.ecl.2004.03.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The near-epidemic proportions of diabetes mellitus and the metabolic syndrome over the past years are widely ascribed to a changing socioeconomic environment that contributes to excessive nutritional intake and sedentary lifestyle. Paradoxically, this gives room for expectations, because timely lifestyle and dietary intervention could decelerate the progression of diabetes, reduce the rate of development of cardiovascular complications, and reduce costs associated with treatment and rehabilitation. This approach, however, depends on the development of tools that allow precise estimation of risk of cardiovascular complications before the onset of diabetes mellitus and the risk of developing type 2 diabetes itself. This article reviews the progress that has been made toward reaching these goals based on the results of the PROspective Cardiovascular Munster (PROCAM) study.
引用
收藏
页码:377 / +
页数:17
相关论文
共 50 条
  • [1] Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study
    G Assmann
    H Schulte
    U Seedorf
    [J]. International Journal of Obesity, 2008, 32 : S11 - S16
  • [2] Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study
    Assmann, G.
    Schulte, H.
    Seedorf, U.
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2008, 32 (Suppl 2) : S11 - S16
  • [3] Assessment of cardiovascular risk - PROCAM and new algorithms
    Assmann, G
    [J]. BIOMEDIZINISCHE TECHNIK, 2005, 50 (7-8): : 227 - 232
  • [4] Emerging markers in cardiovascular risk assessment in the PROCAM study
    Assmann, G.
    Cullen, P.
    Stoll, M.
    Schulte, H.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 467 - 467
  • [5] Metabolic syndrome - Cardiovascular risk assessment and management
    Wong, Nathan D.
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2007, 7 (04) : 259 - 272
  • [6] Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view
    Wilson, PWF
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2004, 33 (03) : 467 - +
  • [7] Comparison of Framingham and PROCAM scores for risk assessment of cardiovascular disease in HIV-positive adults with metabolic complications
    Normén, L
    Yip, B
    Montaner, JSG
    Harris, M
    Frohlich, J
    Bondy, G
    Hogg, RS
    [J]. ANTIVIRAL THERAPY, 2004, 9 (06) : L66 - L67
  • [8] Cardiovascular risk associated with obesity and metabolic syndrome: the European point of view
    Tounian, P.
    [J]. ARCHIVES DE PEDIATRIE, 2009, 16 (06): : 687 - 688
  • [9] Prevalence of (un)diagnosed cardiovascular risk factors and metabolic syndrome with comparison of FRS, PROCAM, SCORE, and ASCVD risk equation models in an Austrian workplace
    Rittmannsberger, B.
    Luger, M.
    Luger, E.
    Daemon, S.
    Hoefler, J.
    Angelmaier, L.
    Maschke, K.
    Sakho, C.
    Pfeiffenberger, A.
    Schaetzer, M.
    Lechleitner, M.
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 (SUPPL 1) : S35 - S36
  • [10] Prevalence of (un)diagnosed cardiovascular risk factors and metabolic syndrome with comparison of FRS, PROCAM, SCORE, and ASCVD risk equation models in an Austrian workplace
    Rittmannsberger, B.
    Luger, M.
    Luger, E.
    Daemon, S.
    Hoefler, J.
    Angelmaier, L.
    Maschke, K.
    Sakho, C.
    Pfeiffenberger, A.
    Schaetzer, M.
    Lechleitner, M.
    Hoppichler, F.
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 : S35 - S36